Compare TCRX & CPHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TCRX | CPHI |
|---|---|---|
| Founded | 2018 | N/A |
| Country | United States | China |
| Employees | N/A | 221 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.4M | 41.3M |
| IPO Year | 2021 | 2008 |
| Metric | TCRX | CPHI |
|---|---|---|
| Price | $0.24 | $0.88 |
| Analyst Decision | Hold | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $1.00 | N/A |
| AVG Volume (30 Days) | 761.4K | ★ 3.9M |
| Earning Date | 11-11-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.28 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,325,000.00 | $4,144,268.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 266.65 | N/A |
| 52 Week Low | $0.22 | $0.38 |
| 52 Week High | $2.57 | $19.19 |
| Indicator | TCRX | CPHI |
|---|---|---|
| Relative Strength Index (RSI) | 24.14 | 55.89 |
| Support Level | N/A | $0.53 |
| Resistance Level | $0.37 | $0.91 |
| Average True Range (ATR) | 0.03 | 0.15 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 12.62 | 42.24 |
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.